The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Systems biology-based investigation of cooperating microRNAs as monotherapy or adjuvant therapy in cancer
Open accessAbstract
MicroRNAs (miRNAs) are short, noncoding RNAs that regulate gene expression by suppressing mRNA translation and reducing mRNA stability. A miRNA can potentially bind many mRNAs, thereby affecting the expression of oncogenes and tumor suppressor genes as well as the activity of whole pathways. The promise of miRNA therapeutics in cancer is to harness this evolutionarily conserved mechanism for the coordinated regulation of gene expression, and thus restoring a normal cell phenotype. However, the promiscuous binding of miRNAs can provoke unwanted off-target effects, which are usually caused by high-dose single-miRNA treatments. Thus, it is desirable to develop miRNA therapeutics with increased specificity and efficacy. To achieve that, we propose the concept of miRNA cooperativity in order to exert synergistic repression on target genes, thus lowering the required total amount of miRNAs. We first review miRNA therapies in clinical application. Next, we summarize the knowledge on the molecular mechanism and biological function of miRNA cooperativity and discuss its application in cancer therapies. We then propose and discuss a systems biology approach to investigate miRNA cooperativity for the clinical setting. Altogether, we point out the potential of miRNA cooperativity to reduce off-target effects and to complement conventional, targeted, or immune-based therapies for cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Predicting effective microRNA target sites in mammalian mRNAs
Agarwal, V., Bell, G. W., Nam, J.-W., & Bartel, D. P. (2015) · eLife · doi:10.7554/elife.05005 · Cited by 7,318 · cited 1×
“An intuitive strategy is to combine gene expression analysis with miRNA target prediction algorithms, such as TargetScan (30).”
MethodMicroRNA therapeutics: towards a new era for the management of cancer and other diseases
Rupaimoole, R., & Slack, F. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.246 · Cited by 4,741 · cited 1×
“Besides cancer, miRNA therapeutics have also been tested in other diseases like hepatitis C (28) and type 2 diabetes (29), and some of them have already succeeded in phase II trials (10).”
BackgroundSilencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949 · cited 1×
“miRNA antagonists designed with complementary sequences to oncomiRs prevent them from being loaded into Argonaute proteins, thereby reducing suppression of their tumor suppressor gene targets (18,19).”
BackgroundBartel, D. P. (2018) · Cell · doi:10.1016/j.cell.2018.03.006 · Cited by 3,751
From molecular to modular cell biology.
Hartwell, L. H., Hopfield, J. J., Leibler, S., & Murray, A. W. (1999) · Nature · doi:10.1038/35011540 · Cited by 3,632 · cited 1×
“Thus, we need to modularize the network to understand general principles that govern the structure and behavior of a biological system (72).”
BackgroundGenomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448 · cited 2×
“We derived a core regulatory network by combining network motifs, network topology and gene expression profiles that were measured in melanoma biopsies from patients who received anti-PD1 immunotherapy (76).”
Widespread changes in protein synthesis induced by microRNAs
Selbach, M., Schwanhäusser, B., Thierfelder, N., Fang, Z., Khanin, R., & Rajewsky, N. (2008) · Nature · doi:10.1038/nature07228 · Cited by 3,429 · cited 1×
“As a single miRNA often represses its targets quite weakly (21,32), high doses of effective miRNA mimics are usually required to achieve the expected effect.”
BackgroundNetwork motifs: theory and experimental approaches
Alon, U. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2102 · Cited by 3,279
SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase
Bennett, B. L., Sasaki, D. T., Murray, B. W., O'Leary, E. C., Sakata, S. T., Xu, W., Leisten, J. C., Motiwala, A., Pierce, S., Satoh, Y., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251194298 · Cited by 2,558 · cited 1×
“JUN miR-9-5p* (D) miR-494-3p* (U) Small molecule (121) Overexpressed in a large fraction of human melanoma samples; Promote cell proliferation and tumor”
BackgroundRegulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
Singh, R., Letai, A., & Sarosiek, K. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0089-8 · Cited by 2,111 · cited 2×
“Rrg-Gly-Asp-based peptides (125) Promote apoptosis; Regulate the mitochondrial apoptosis pathway (17,91,111,124,125)”
BackgroundMicroRNAs in cancer: biomarkers, functions and therapy
Hayes, J., Peruzzi, P. P., & Lawler, S. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.06.005 · Cited by 2,049
MicroRNAs 103 and 107 regulate insulin sensitivity
Trajkovski, M., Hausser, J., Soutschek, J., Bhat, B., Akin, A., Zavolan, M., Heim, M. H., & Stoffel, M. (2011) · Nature · doi:10.1038/nature10112 · Cited by 1,000 · cited 1×
“Besides cancer, miRNA therapeutics have also been tested in other diseases like hepatitis C (28) and type 2 diabetes (29), and some of them have already succeeded in phase II trials (10).”
BackgroundMicroRNA-Mediated Feedback and Feedforward Loops Are Recurrent Network Motifs in Mammals
Tsang, J., Zhu, J., & van Oudenaarden, A. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.018 · Cited by 740
Identifying miRNAs, targets and functions
Liu, B., Li, J., & Cairns, M. J. (2014) · Briefings in Bioinformatics · doi:10.1093/bib/bbs075 · Cited by 563
MDM2 inhibitors for cancer therapy
Vassilev, L. T. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.11.002 · Cited by 532
Combining two strategies to improve perfusion and drug delivery in solid tumors
Stylianopoulos, T., & Jain, R. K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318415110 · Cited by 508
Pencheva, N., Tran, H., Buss, C., Huh, D., Drobnjak, M., Busam, K., & Tavazoie, S. F. (2012) · Cell · doi:10.1016/j.cell.2012.10.028 · Cited by 415 · cited 2×
“APOE, DNAJA4 miR-1908, miR-199a, miR-199a Inhibitors Synergistic Metastasis Melanoma (in vitro, in vivo) (34)”
BackgroundDenzler, R., McGeary, S. E., Title, A. C., Agarwal, V., Bartel, D. P., & Stoffel, M. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.09.027 · Cited by 340
Malhotra, M., Sekar, T. V., Ananta, J. S., Devulapally, R., Afjei, R., Babikir, H. A., Paulmurugan, R., & Massoud, T. F. (2018) · Oncotarget · doi:10.18632/oncotarget.25135 · Cited by 71 · cited 2×
“For instance, miRNA modulation can be used to increase the efficiency of small-molecule inhibitors targeting oncogenes (39) and to lower effective doses of chemotherapies (40).”
BackgroundBax mRNA therapy using cationic liposomes for human malignant melanoma
Okumura, K., Nakase, M., Inui, M., Nakamura, S., Watanabe, Y., & Tagawa, T. (2008) · The Journal of Gene Medicine · doi:10.1002/jgm.1214 · Cited by 31
Cited by
Emerging concepts of miRNA therapeutics: from cells to clinic
Diener, C., Keller, A., & Meese, E. (2022) · Trends in Genetics · doi:10.1016/j.tig.2022.02.006 · Cited by 971
miRNet 2.0: network-based visual analytics for miRNA functional analysis and systems biology
Chang, L., Zhou, G., Soufan, O., & Xia, J. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa467 · Cited by 880
Artificial intelligence in cancer target identification and drug discovery
You, Y., Lai, X., Pan, Y., Zheng, H., Vera, J., Liu, S., Deng, S., & Zhang, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00994-0 · Cited by 435
Self-citationRNAi-based therapeutics and tumor targeted delivery in cancer
Kara, G., Calin, G. A., & Ozpolat, B. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114113 · Cited by 411
The miRNA–target interactions: An underestimated intricacy
Diener, C., Keller, A., & Meese, E. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkad1142 · Cited by 248
Metadata
- Authors
- Lai, X., Eberhardt, M., Schmitz, U., & Vera, J.
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-07-24
- Volume
- 47
- Issue
- 15
- Pages
- 7753-7766
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- OpenAlex
- W2963934840
- Cited by
- 170
- References
- 20
- FWCI
- 7.12
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.